Fulgent Therapeutics

Fulgent Pharma is a privately held company dedicated to the development of clinical-stage medications specifically for cancer treatment. It focuses on creating both improved chemotherapy drugs through nanoencapsulation and innovative new drug candidates. The company aims to address a wide spectrum of cancers, including breast, lung, ovarian, colon, and pancreatic cancer, with the goal of enhancing therapeutic options for patients. Through its research and development efforts, Fulgent Pharma seeks to advance the effectiveness and precision of cancer therapies.

Inform Diagnostics, Inc. is a healthcare company specializing in anatomic pathology services across various fields, including breast health, dermatology, gastroenterology, hematology, and urology. Headquartered in Irving, Texas, with additional laboratories in Phoenix, Arizona, and Boston, Massachusetts, the company focuses on providing diagnostic solutions that enhance clinical decision-making. Inform Diagnostics is particularly noted for its development of a blood-based diagnostics platform aimed at addressing unmet clinical needs in gastrointestinal cancers, encompassing screening, diagnosis, prognosis, and therapeutic guidance. The company also offers specialized urologic pathology services, including microscopy and immunohistochemistry, and proprietary tests such as EoGenius for eosinophilic esophagitis and UroVysion for detecting genetic changes in bladder cells. Furthermore, Inform Diagnostics provides general surgery pathology services and healthcare consulting, particularly concerning regulatory requirements, to support pharmaceutical companies and other healthcare entities. Established in 1996, the company was previously known as Miraca Life Sciences, Inc. before rebranding in January 2018.

Spatial Genomics is a leader in spatial analysis, focusing on the development of sequential fluorescence technology to identify multiple RNA transcripts within individual cells. This innovative approach preserves the spatial context of the data, allowing researchers to map gene expression accurately. By providing tools that enhance the understanding of cellular behavior in relation to their environment, Spatial Genomics aims to facilitate significant advancements in biological research and contribute to the creation of comprehensive human cell atlases. The company's commitment to empowering discovery positions its technology as a potential standard research tool for laboratories globally.

CSI Laboratories, founded in 1997, began as a flow cytometry laboratory dedicated to serving its regional community with specialized diagnostic testing. Over the years, the company has expanded its offerings to include cytogenetics and molecular genetics, establishing FISH laboratories in 2005. In 2007, it further enhanced its capabilities by launching an extensive immunohistochemistry laboratory. CSI Laboratories focuses on providing personalized and clinically significant diagnostic testing for hematopathology and surgical pathology clients. Its services include flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization, molecular genetics, next-generation sequencing, and expert consultations. With a commitment to client service and patient care, CSI Laboratories aims to deliver the diagnostic expertise that pathologists and clinicians require.

FF Gene Biotech was founded to bring Fulgent Genetics’ Next Generation Sequencing (NGS) capabilities to the Chinese genetic testing market.

Helio Health is an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw. The company’s mission is to simplify cancer screening so lives can be saved by detecting cancer earlier. With Helio’s AI-driven technology, both physicians and their patients gain powerful insights from accurate, accessible, and convenient blood tests. Helio’s development program is focused on liver, colon, breast and lung cancer. Helio Health is headquartered in Irvine, CA, with R&D, GMP and CLIA facilities in Irvine, CA and West Lafayette, IN.